Gizzo Salvatore, Noventa Marco, Quaranta Michela, Vitagliano Amerigo, Saccardi Carlo, Litta Pietro, Antona Donato
Department of Woman and Child Health, University of Padua, I-35128 Padua, Italy.
Department of Obstetrics and Gynecology, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK.
Oncol Lett. 2017 Feb;13(2):549-553. doi: 10.3892/ol.2016.5493. Epub 2016 Dec 14.
The lethality of epithelial ovarian cancer (EOC) may be due to common misconceptions regarding etiology and the absence of effective screening and early diagnostic tools. Reviews of histopathological surveys performed on the resected fallopian tubes of breast cancer (BRCA) mutation carriers, who underwent risk-reducing salpingo-oophorectomy, unexpectedly revealed the presence of occult carcinomas of the fallopian tubes. This finding prompted studies that demonstrated the most accredited theory of type II EOC development, which suggests that a large proportion of these tumors are derived from the fallopian tube. At present, no diagnostic tools or screening programs have been demonstrated to be effective or cost-effective in improving the outcome of EOC; it is therefore imperative that the scientific community unite its efforts in the identification of a valid screening and/or early diagnostic method for the treatment of this lethal gynecological malignancy. To this end, the present paper proposes a novel tool for the screening/early diagnosis of EOC: The 'Tuba-check'. This novel approach is based on the possibility of acquiring specimens for tubal lumen cytology via hysteroscopy in a minimally-invasive outpatient setting. The present study protocol aimed to validate the technical feasibility and oncological accuracy of the proposed approach, commencing with a cohort of patients with an expected increased oncological risk, including BRCA mutation carriers or those with a gene expression profile of 'BRCA-ness'. If the data collected by the present study protocol validates this approach, the 'Tuba-check' may, in the near future, be extended for the treatment of all women, therefore reducing the number of victims of epithelial ovarian carcinoma.
上皮性卵巢癌(EOC)的致死率可能归因于对病因的普遍误解以及缺乏有效的筛查和早期诊断工具。对接受降低风险的输卵管卵巢切除术的乳腺癌(BRCA)突变携带者切除的输卵管进行组织病理学调查时,意外发现了输卵管隐匿性癌。这一发现促使了相关研究,这些研究证实了II型EOC发展的最可靠理论,即这些肿瘤很大一部分起源于输卵管。目前,尚未证明任何诊断工具或筛查项目在改善EOC的治疗结果方面是有效或具有成本效益的;因此,科学界必须共同努力,确定一种有效的筛查和/或早期诊断方法来治疗这种致命的妇科恶性肿瘤。为此,本文提出了一种用于EOC筛查/早期诊断的新工具:“输卵管检查”。这种新方法基于在微创门诊环境中通过宫腔镜获取输卵管腔细胞学标本的可能性。本研究方案旨在验证所提出方法的技术可行性和肿瘤学准确性,首先从一组预期肿瘤风险增加的患者开始,包括BRCA突变携带者或具有“BRCA样”基因表达谱的患者。如果本研究方案收集的数据验证了这种方法,“输卵管检查”可能在不久的将来扩展到所有女性的治疗,从而减少上皮性卵巢癌的受害者数量。